Cytarabine liposomal (DepoCyt)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2][3]
Route: IT
Extravasation: irritant

  • "In-line filters must not be used when administering DepoCyt."[1]

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2001-07-11: Initial authorization as DepoCyte
  • 2018-07-10: Withdrawn on request from the manufacturer, for commercial reasons

Also known as

  • Generic name: Liposomal Ara-C
  • Brand name: DepoCyt, DepoCyte